# EDGAR Filing Document

**Accession Number:** 0001761055
**File Stem:** 0001410368-26-066749
**Filing Date:** 2026-6
**Character Count:** 34900
**Document Hash:** 58b1b8ce595f9aac56c3632fee6da01e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-066749.hdr.sgml**: 20260625

**ACCESSION NUMBER**: 0001410368-26-066749

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260625

**DATE AS OF CHANGE**: 20260625

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock ETF Trust
- **CENTRAL INDEX KEY:** 0001761055

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23402
- **FILM NUMBER:** 261121672

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 8004417762

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

| Class ID   | Class Name                           | Ticker Symbol   |
|:---|:---|:---|
| C000221226 | iShares Health Innovation Active ETF |  |

## Nport-Ex

April 30, 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

2026 Quarterly Report <br>&nbsp;&nbsp;&nbsp;&nbsp;(Unaudited)<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| **BlackRock ETF Trust** |
| • iShares Health Innovation Active ETF \| BMED \| NYSE Arca |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Not FDIC Insured • May Lose Value • No Bank Guarantee**<br>

------

Schedule of Investments (unaudited)

April 30, 2026

**iShares Health Innovation Active ETF**

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 34.0%** | **Biotechnology — 34.0%** | **Biotechnology — 34.0%** |
| Amgen, Inc. | &nbsp;&nbsp;&nbsp; 1342 | $464667 |
| Apogee Therapeutics, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 576 | 47745 |
| Argenx SE, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 368 | 287673 |
| Biogen, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1935 | 366257 |
| BioMarin Pharmaceutical, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2280 | 122915 |
| BioNTech SE, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 507 | 52449 |
| Cogent Biosciences, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 4393 | 157225 |
| Dianthus Therapeutics, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 651 | 57158 |
| Eikon Therapeutics, Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1253 | 12048 |
| Erasca, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1251 | 13323 |
| Gilead Sciences, Inc. | &nbsp;&nbsp;&nbsp; 4165 | 544949 |
| Incyte Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1645 | 156719 |
| Insmed, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1326 | 180773 |
| Moderna, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5804 | 266636 |
| Protagonist Therapeutics, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2031 | 201008 |
| Revolution Medicines, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 723 | 104199 |
| Sagimet Biosciences, Inc., Class A, NVS<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1688 | 13555 |
| Summit Therapeutics, Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 3507 | 75260 |
| Ultragenyx Pharmaceutical, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 460 | 11357 |
| Vertex Pharmaceuticals, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 690 | 294892 |
|  |  | 3430808 |
| **Health Care Equipment & Supplies — 14.2%** | **Health Care Equipment & Supplies — 14.2%** | **Health Care Equipment & Supplies — 14.2%** |
| Alcon AG | &nbsp;&nbsp;&nbsp; 1360 | 101823 |
| Boston Scientific Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2435 | 140281 |
| Dexcom, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3493 | 208008 |
| Edwards Lifesciences Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5726 | 478121 |
| IDEXX Laboratories, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 256 | 143565 |
| Intuitive Surgical, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 651 | 297904 |
| Medline, Inc., Class A<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1459 | 64882 |
|  |  | 1434584 |
| **Life Sciences Tools & Services — 21.3%** | **Life Sciences Tools & Services — 21.3%** | **Life Sciences Tools & Services — 21.3%** |
| Bio-Techne Corp. | &nbsp;&nbsp;&nbsp; 3805 | 210493 |
| Bruker Corp. | &nbsp;&nbsp;&nbsp; 6389 | 234540 |
| Charles River Laboratories International, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1783 | 297707 |
| Danaher Corp. | &nbsp;&nbsp;&nbsp; 1398 | 250172 |
| Mettler-Toledo International, Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 245 | 312769 |
| Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;&nbsp; 408 | 195416 |
| Waters Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1035 | 320053 |
| Wuxi Biologics Cayman, Inc.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 76000 | 324729 |
|  |  | 2145879 |
| **Pharmaceuticals — 26.1%** | **Pharmaceuticals — 26.1%** | **Pharmaceuticals — 26.1%** |
| AstraZeneca PLC | &nbsp;&nbsp;&nbsp; 875 | 163949 |
| Bristol-Myers Squibb Co. | &nbsp;&nbsp;&nbsp; 2169 | 131420 |
| GSK PLC, ADR, NVS | &nbsp;&nbsp;&nbsp; 3926 | 205369 |
| Johnson & Johnson | &nbsp;&nbsp;&nbsp; 3459 | 795051 |
| Merck & Co., Inc. | &nbsp;&nbsp;&nbsp; 3620 | 395231 |
| Novartis AG, Registered | &nbsp;&nbsp;&nbsp; 1579 | 233360 |
| Pfizer, Inc. | &nbsp;&nbsp;&nbsp; 9393 | 250793 |
| Roche Holding AG, NVS | &nbsp;&nbsp;&nbsp; 446 | 181745 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Pharmaceuticals (continued)** | **Pharmaceuticals (continued)** | **Pharmaceuticals (continued)** |
| Teva Pharmaceutical Industries Ltd., ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3386 | $118747 |
| UCB SA | &nbsp;&nbsp;&nbsp; 586 | 159563 |
|  |  | 2635228 |
| **Total Common Stocks — 95.6%** <br>**(Cost: $9,821,027)** | **Total Common Stocks — 95.6%** <br>**(Cost: $9,821,027)** | 9646499 |
| **Rights** | **Rights** | **Rights** |
| **Biotechnology — 0.0%** | **Biotechnology — 0.0%** | **Biotechnology — 0.0%** |
| Blueprint Medicines Corp., CVR, NVS <sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 110 | 110 |
| Contra Mirati Therapeutics, Inc., CVR, NVS <sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 334 | 264 |
| Vigil Neuroscience, Inc., CVR<sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 484 | 24 |
|  |  | 398 |
| **Health Care Equipment & Supplies — 0.0%** | **Health Care Equipment & Supplies — 0.0%** | **Health Care Equipment & Supplies — 0.0%** |
| Abiomed, Inc., CVR, NVS <sup>(d)</sup> | &nbsp;&nbsp;&nbsp; 246 | 371 |
| **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** | **Industrial Conglomerates — 0.0%** |
| Frequency Therapeutics, Inc., CVR, NVS <sup>(a)(d)</sup> | &nbsp;&nbsp;&nbsp; 420 |  |
| **Total Rights — 0.0%** <br>**(Cost: $560)** | **Total Rights — 0.0%** <br>**(Cost: $560)** | 769 |
| **Total Long-Term Investments — 95.6%** <br>**(Cost: $9,821,587)** | **Total Long-Term Investments — 95.6%** <br>**(Cost: $9,821,587)** | 9647268 |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 4.6%** | **Money Market Funds — 4.6%** | **Money Market Funds — 4.6%** |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency Shares, <br> 3.83%<sup>(e)(f)(g)</sup><br>| &nbsp;&nbsp;&nbsp; 26223 | 26231 |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency Shares, <br> 3.61%<sup>(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp; 440000 | 440000 |
| **Total Short-Term Securities — 4.6%** <br>**(Cost: $466,213)** | **Total Short-Term Securities — 4.6%** <br>**(Cost: $466,213)** | 466231 |
| **Total Investments — 100.2%** <br>**(Cost: $10,287,800)** | **Total Investments — 100.2%** <br>**(Cost: $10,287,800)** | 10113499 |
| **Liabilities in Excess of Other Assets — (0.2)%** | **Liabilities in Excess of Other Assets — (0.2)%** | (18363)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | $10095136 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of this security is on loan.

<sup>(c)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. 

<sup>(d)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(e)</sup> Affiliate of the Fund.

<sup>(f)</sup> Annualized 7-day yield as of period end.

<sup>(g)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

------

Schedule of Investments (unaudited)(continued)

April 30, 2026

**iShares Health Innovation Active ETF**

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Fund during the period ended April 30, 2026 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*07/31/25*<br>| *Purchases* <br>*at Cost*<br>| *Proceeds* <br>*from Sales*<br>| &nbsp;&nbsp; *Net Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*04/30/26*<br>| *Shares* <br>*Held at* <br>*04/30/26*<br>| *Income* | &nbsp;&nbsp; *Capital* <br>*Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| BlackRock Cash Funds: Institutional, SL Agency Shares | $183837 | $— | &nbsp;&nbsp; $(157717 )<sup>(a)</sup><br>| $125 | $(14)<br>| $26231 | 26223 | $1229 <br><sup>(b)</sup><br>| $— |
| BlackRock Cash Funds: Treasury, SL Agency Shares | &nbsp;&nbsp;&nbsp; 50000 | 390000 <br><sup>(a)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp; 440000 | 440000 | &nbsp;&nbsp; 6219 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |
|  |  |  |  | $125 | $(14) | $466231 |  | $7448 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

**Fair Value Hierarchy as of Period End** 

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges that the Fund has the ability to access for identical assets or liabilities;

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks | &nbsp;&nbsp; $8747102 | &nbsp;&nbsp; $899397 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $9646499 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rights | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 769 | &nbsp;&nbsp; 769 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 466231 | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 466231 |
|  | &nbsp;&nbsp; $9213333 | &nbsp;&nbsp; $899397 | &nbsp;&nbsp; $769 | &nbsp;&nbsp; $10113499 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation** | **Portfolio Abbreviation** |
| ADR | American Depositary Receipt |
| NVS | Non-Voting Shares |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** BlackRock ETF Trust

- **b. Investment Company Act file number:** 811-23402

- **c. CIK number of Registrant:** 0001761055

- **d. LEI of Registrant:** 5493007WBHAKV9JVS642

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 BELLEVUE PARKWAY

  - **City:** WILMINGTON

  - **State:** DE

  - **Foreign country:** US

  - **Zip / Postal Code:** 19809

  - **Telephone number:** 800-441-7762

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares Health Innovation Active ETF

- **b. EDGAR series identifier (if any):** S000069260

- **c. LEI of Series:** 549300QSHQQEGUGOU050

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2026-04-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $10151687.39

**Total Liabilities:** $56562.91

**Net Assets:** $10095124.48

**Cash Not Reported:** $3611.53

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000221226 | -0.08%               | -6.94%               | -2.91%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $156207.49               | $-155805.24                                |
| Month 2  | $63732.12                | $-850380.39                                |
| Month 3  | $-38223.03               | $-263998.79                                |

**Designated Index Information**

- **Index Name:** STOXX GLOBAL BREAKTHROUGH HEALTHCARE

- **Index Identifier:** STFSHIUN

### Schedule of Portfolio Investments

| Name                                           | Title                                                 | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Charles River Laboratories International Inc   | Charles River Laboratories International Inc          | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |      1783 | NS      | $297707.51    | 2.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics Inc                   | Protagonist Therapeutics Inc                          | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2031 | NS      | $201008.07    | 1.99%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                    | BioNTech SE                                           | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |       507 | NS      | $52449.15     | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                     | Vertex Pharmaceuticals Inc                            | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |       690 | NS      | $294892.20    | 2.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                              | Johnson & Johnson                                     | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |      3459 | NS      | $795051.15    | 7.88%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA MIRATI THERAPEU                         | CONTRA MIRATI THERAPEU                                | CUSIP: 604CVR027<br>LEI: 529900GYRW59IDQV6N54 | Long             |  | CORP              | US        |       334 | NS      | $263.86       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| CONTRA FREQUENCY THERA                         | CONTRA FREQUENCY THERA                                | CUSIP: 358CVR025<br>LEI: N/A                  | Long             |  | CORP              | US        |       420 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| CONTRA BLUEPRINT MEDIC                         | CONTRA BLUEPRINT MEDIC                                | CUSIP: 096CVR048<br>LEI: 5299004CC60O9T5HVM83 | Long             |  | CORP              | US        |       110 | NS      | $110.00       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Thermo Fisher Scientific Inc                   | Thermo Fisher Scientific Inc                          | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |       408 | NS      | $195415.68    | 1.94%             |  |  |  | No            |                  1 | On Loan: No      |
| BioMarin Pharmaceutical Inc                    | BioMarin Pharmaceutical Inc                           | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |      2280 | NS      | $122914.80    | 1.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Erasca Inc                                     | Erasca Inc                                            | CUSIP: 29479A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1251 | NS      | $13323.15     | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Bruker Corp                                    | Bruker Corp                                           | CUSIP: 116794108<br>LEI: LEBZ6VLQ6I8XB1NHVY15 | Long             | EC               | CORP              | US        |      6389 | NS      | $234540.19    | 2.32%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                                | AstraZeneca PLC                                       | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |       875 | NS      | $163948.75    | 1.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Alcon AG                                       | Alcon AG                                              | CUSIP: 000000000<br>LEI: 549300LDT5AP8S0NBM78 | Long             | EC               | CORP              | CH        |      1360 | NS      | $101823.20    | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp                         | Boston Scientific Corp                                | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |      2435 | NS      | $140280.35    | 1.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Eikon Therapeutics Inc                         | Eikon Therapeutics Inc                                | CUSIP: 282564103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1253 | NS      | $12047.60     | 0.12%             |  |  |  | No            |                  1 | On Loan: —       |
| Biogen Inc                                     | Biogen Inc                                            | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |      1935 | NS      | $366256.80    | 3.63%             |  |  |  | No            |                  1 | On Loan: No      |
| GSK PLC                                        | GSK PLC                                               | CUSIP: 37733W204<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |      3926 | NS      | $205369.06    | 2.03%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA ABIOMED INC                             | CONTRA ABIOMED INC                                    | CUSIP: 003CVR016<br>LEI: N/A                  | Long             |  | CORP              | US        |       246 | NS      | $371.46       | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| BlackRock Funds III                            | BlackRock Cash Funds: Institutional, SL Agency Shares | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |     25630 | NS      | $25637.93     | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                       | Revolution Medicines Inc                              | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |       723 | NS      | $104198.76    | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                                    | Moderna Inc                                           | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |      5804 | NS      | $266635.76    | 2.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics Inc                      | Dianthus Therapeutics Inc                             | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |       651 | NS      | $57157.80     | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Wuxi Biologics Cayman Inc                      | Wuxi Biologics Cayman Inc                             | CUSIP: 000000000<br>LEI: 5493001TD2TH6VDTJU11 | Long             | EC               | CORP              | KY        |     76000 | NS      | $324728.69    | 3.22%             |  |  |  | No            |                  2 | On Loan: No      |
| Sagimet Biosciences Inc                        | Sagimet Biosciences Inc                               | CUSIP: 786700104<br>LEI: 2549002OT2F8BV0VPD02 | Long             | EC               | CORP              | US        |      1688 | NS      | $13554.64     | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                    | Incyte Corp                                           | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |      1645 | NS      | $156719.15    | 1.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical Inc                         | Intuitive Surgical Inc                                | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |       651 | NS      | $297904.11    | 2.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                      | Amgen Inc                                             | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      1342 | NS      | $464667.50    | 4.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                     | Dexcom Inc                                            | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |      3493 | NS      | $208008.15    | 2.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                                     | Pfizer Inc                                            | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |      9393 | NS      | $250793.10    | 2.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                                | Bio-Techne Corp                                       | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |      3805 | NS      | $210492.60    | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                         | UCB SA                                                | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |       586 | NS      | $159562.69    | 1.58%             |  |  |  | No            |                  2 | On Loan: No      |
| Edwards Lifesciences Corp                      | Edwards Lifesciences Corp                             | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |      5726 | NS      | $478121.00    | 4.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc                        | Apogee Therapeutics Inc                               | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       576 | NS      | $47744.64     | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                      | Argenx SE                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |       368 | NS      | $287672.96    | 2.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Medline Inc                                    | Medline Inc                                           | CUSIP: 58507V107<br>LEI: 984500FAN6J1P8566D43 | Long             | EC               | CORP              | US        |      1459 | NS      | $64881.73     | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Ultragenyx Pharmaceutical Inc                  | Ultragenyx Pharmaceutical Inc                         | CUSIP: 90400D108<br>LEI: 529900EV44GVDN1DCX77 | Long             | EC               | CORP              | US        |       460 | NS      | $11357.40     | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                     | Insmed Inc                                            | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |      1326 | NS      | $180773.58    | 1.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Cogent Biosciences Inc                         | Cogent Biosciences Inc                                | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      4393 | NS      | $157225.47    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                   | Danaher Corp                                          | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |      1398 | NS      | $250172.10    | 2.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc                        | Summit Therapeutics Inc                               | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      3507 | NS      | $75260.22     | 0.75%             |  |  |  | No            |                  1 | On Loan: —       |
| Novartis AG                                    | Novartis AG                                           | CUSIP: 000000000<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |      1579 | NS      | $233359.89    | 2.31%             |  |  |  | No            |                  2 | On Loan: No      |
| Mettler-Toledo International Inc               | Mettler-Toledo International Inc                      | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |       245 | NS      | $312769.45    | 3.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd             | Teva Pharmaceutical Industries Ltd                    | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |      3386 | NS      | $118747.02    | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                                 | Merck & Co Inc                                        | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |      3620 | NS      | $395231.60    | 3.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Waters Corp                                    | Waters Corp                                           | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |      1035 | NS      | $320053.05    | 3.17%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA VIGIL NEUROSCIE                         | CONTRA VIGIL NEUROSCIE                                | CUSIP: 926CVR010<br>LEI: N/A                  | Long             |  | CORP              | US        |       484 | NS      | $24.20        | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Roche Holding AG                               | Roche Holding AG                                      | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |       446 | NS      | $181744.93    | 1.80%             |  |  |  | No            |                  2 | On Loan: No      |
| IDEXX Laboratories Inc                         | IDEXX Laboratories Inc                                | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |       256 | NS      | $143564.80    | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES | BlackRock Cash Funds: Treasury, SL Agency Shares      | CUSIP: 066922477<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |    440000 | NS      | $440000.00    | 4.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co                        | Bristol-Myers Squibb Co                               | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |      2169 | NS      | $131419.71    | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                            | Gilead Sciences Inc                                   | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      4165 | NS      | $544948.60    | 5.40%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-05-29

**Name of Applicant:** BlackRock ETF Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer